• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用组织型纤溶酶原激活剂进行冠状动脉血栓选择性溶栓治疗。

Clot-selective coronary thrombolysis with tissue-type plasminogen activator.

作者信息

Bergmann S R, Fox K A, Ter-Pogossian M M, Sobel B E, Collen D

出版信息

Science. 1983 Jun 10;220(4602):1181-3. doi: 10.1126/science.6602378.

DOI:10.1126/science.6602378
PMID:6602378
Abstract

Coronary thrombolysis, an intervention that can abort the sequelae of acute myocardial infarction, was accomplished within 10 minutes in dogs by intravenous administration of clot-selective, tissue-type plasminogen activator. In addition to inducing clot lysis, this promising fibrinolytic agent restored intermediary metabolism and nutritional myocardial blood flow, detectable noninvasively with positron tomography, without inducing a systemic fibrinolytic state.

摘要

冠状动脉溶栓是一种能够中止急性心肌梗死后遗症的干预措施,通过静脉注射凝块选择性组织型纤溶酶原激活剂,在犬类动物中10分钟内即可完成。除了诱导凝块溶解外,这种有前景的纤溶药物还能恢复中间代谢和心肌营养血流,用正电子断层扫描可无创检测到,且不会诱发全身纤溶状态。

相似文献

1
Clot-selective coronary thrombolysis with tissue-type plasminogen activator.使用组织型纤溶酶原激活剂进行冠状动脉血栓选择性溶栓治疗。
Science. 1983 Jun 10;220(4602):1181-3. doi: 10.1126/science.6602378.
2
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.组织型纤溶酶原激活剂用于进展性心肌梗死患者的冠状动脉溶栓治疗。
N Engl J Med. 1984 Mar 8;310(10):609-13. doi: 10.1056/NEJM198403083101001.
3
Coronary thrombolysis with clot-selective plasminogen activators.使用凝块选择性纤溶酶原激活剂进行冠状动脉溶栓治疗。
Herz. 1986 Feb;11(1):9-15.
4
Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.
Circulation. 1984 May;69(5):983-90. doi: 10.1161/01.cir.69.5.983.
5
Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
Circulation. 1984 Mar;69(3):605-10. doi: 10.1161/01.cir.69.3.605.
6
Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion.
J Am Coll Cardiol. 1985 Jan;5(1):85-91. doi: 10.1016/s0735-1097(85)80088-7.
7
Coronary thrombolysis for evolving myocardial infarction.进展性心肌梗死的冠状动脉溶栓治疗。
Drugs. 1984 Nov;28(5):465-83. doi: 10.2165/00003495-198428050-00004.
8
Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis.
Thromb Haemost. 1996 Dec;76(6):1096-101.
9
Thrombolysis for evolving myocardial infarction. Health and Public Policy Committee, American College of Physicians.急性心肌梗死的溶栓治疗。美国医师协会健康与公共政策委员会
Ann Intern Med. 1985 Sep;103(3):463-9.
10
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.

引用本文的文献

1
A facultative plasminogen-independent thrombolytic enzyme from Sipunculus nudus.一种来自裸体方格星虫的兼性非纤溶酶原依赖性溶栓酶。
Nat Commun. 2025 Apr 24;16(1):3852. doi: 10.1038/s41467-025-58915-y.
2
Four Decades of Ischemic Penumbra and Its Implication for Ischemic Stroke.缺血半暗带的四十年及其对缺血性脑卒中的影响。
Transl Stroke Res. 2021 Dec;12(6):937-945. doi: 10.1007/s12975-021-00916-2. Epub 2021 Jul 5.
3
Lysis of arterial thrombi by perfusion of N,N'-Diacetyl-L-cystine (DiNAC).N,N'-二乙酰-L-半胱氨酸(DiNAC)灌注溶解动脉血栓。
PLoS One. 2021 Feb 25;16(2):e0247496. doi: 10.1371/journal.pone.0247496. eCollection 2021.
4
Insights from thrombi retrieved in stroke due to large vessel occlusion.大血管闭塞性脑卒中血栓取出术中的新发现。
J Cereb Blood Flow Metab. 2019 Aug;39(8):1433-1451. doi: 10.1177/0271678X19856131. Epub 2019 Jun 18.
5
Professor Keith AA Fox.基思·AA·福克斯教授
Eur Cardiol. 2016 Aug;11(1):60-61. doi: 10.15420/ecr.2016.11.1.60.
6
Human epicardial cell-conditioned medium contains HGF/IgG complexes that phosphorylate RYK and protect against vascular injury.人心脏外膜细胞条件培养基含有可使RYK磷酸化并预防血管损伤的HGF/IgG复合物。
Cardiovasc Res. 2015 Jul 15;107(2):277-86. doi: 10.1093/cvr/cvv168. Epub 2015 May 29.
7
Human Tissue Plasminogen Activator Expression in Escherichia coli using Cytoplasmic and Periplasmic Cumulative Power.
Avicenna J Med Biotechnol. 2010 Jul;2(3):131-6.
8
Atherosclerosis and thrombosis: insights from large animal models.动脉粥样硬化与血栓形成:来自大型动物模型的见解
J Biomed Biotechnol. 2011;2011:907575. doi: 10.1155/2011/907575. Epub 2011 Jan 2.
9
Superselective Intra-arterial Thrombolysis for Acute Cardioembolic Stroke in a Child with Idiopathic Dilated Cardiomyopathy. A Case Report.超选择性动脉内溶栓治疗特发性扩张型心肌病患儿的急性心源性脑栓塞。病例报告。
Interv Neuroradiol. 1999 Jun 30;5(2):187-94. doi: 10.1177/159101999900500213. Epub 2001 May 15.
10
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.重组人微栓酶在犬冠状动脉铜线圈致血栓模型中的溶栓疗效。
J Thromb Thrombolysis. 2010 Jul;30(1):46-54. doi: 10.1007/s11239-009-0400-9.